Related Experiment Video
Updated: Jan 6, 2026
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Published on: May 2, 2019
Breakthroughs in the nanoparticle-mediated delivery of siRNA for breast cancer treatment
Davi Trombini Aleixo1, Estael L C Cruz-Cazarim1, Kezia C B Ferreira1
1Department of Pharmaceutical Sciences, Federal University of Juiz de Fora (UFJF), Juiz de Fora, Brazil.
Abstract:
Although breast cancer treatments have improved, challenges like tumor heterogeneity and drug resistance remain. RNA interference (RNAi), especially through small interfering RNA (siRNA), is a promising strategy to silence specific genes and improve clinical outcomes. However, the clinical translation of siRNA has been limited by barriers related to stability, biodistribution, cellular uptake, among others. Nanoparticle-based delivery systems have emerged as transformative platforms to address these limitations, enhancing siRNA protection, targeting, and intracellular release. This review discusses the major breakthroughs in nanoparticle-mediated siRNA delivery for breast cancer treatment, focusing on how innovations in nanocarrier design have enhanced siRNA stability, targeting, and therapeutic efficacy. We highlight key characteristics in RNA interference mechanisms, the evolution of computational tools for optimizing siRNA design, and the approval of RNAi-based therapies that laid the foundation for oncologic applications. Special emphasis is given to the development of lipid, polymeric, and inorganic nanoparticles engineered for efficient siRNA delivery, their role in overcoming drug resistance when combined with conventional therapies, and the current progress of clinical trials against solid tumors. By integrating nanotechnology and RNAi, these breakthroughs offer new opportunities for precise, durable, and personalized strategies in breast cancer treatment, with the potential to transform the current therapeutic landscape.
Insights
Nanoparticle delivery systems enhance small interfering RNA (siRNA) therapy for breast cancer by improving stability and targeting. These advancements offer new hope for overcoming drug resistance and personalizing treatment strategies.
Area of Science:
- Biomedical Engineering
- Oncology
- Molecular Biology
Background:
- Breast cancer treatment faces challenges including tumor heterogeneity and drug resistance.
- RNA interference (RNAi) using small interfering RNA (siRNA) shows promise for gene silencing but faces delivery barriers.
- Nanoparticle delivery systems are crucial for overcoming siRNA limitations in clinical applications.
Purpose of the Study:
- To review breakthroughs in nanoparticle-mediated siRNA delivery for breast cancer.
- To highlight innovations in nanocarrier design for enhanced siRNA stability, targeting, and efficacy.
- To discuss the potential of these strategies in overcoming drug resistance and personalizing cancer therapy.
Main Methods:
- Review of current literature on nanoparticle-based siRNA delivery systems.
- Analysis of advancements in nanocarrier design (lipid, polymeric, inorganic).
- Examination of RNA interference mechanisms and computational tools for siRNA optimization.
Main Results:
- Nanoparticle innovations have significantly improved siRNA stability, biodistribution, and cellular uptake.
- Engineered nanoparticles enhance targeted delivery and therapeutic efficacy of siRNA in breast cancer models.
- Combination therapies using siRNA nanoparticles show potential in overcoming conventional drug resistance.
Conclusions:
- Nanotechnology integrated with RNAi offers precise and durable therapeutic strategies for breast cancer.
- Further development of nanoparticle-mediated siRNA delivery holds significant promise for personalized oncology.
- Clinical trials are progressing, indicating a transformative potential for breast cancer treatment.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...